Growth Metrics

Catalyst Pharmaceuticals (CPRX) Income from Continuing Operations (2010 - 2026)

Catalyst Pharmaceuticals posted quarterly Income from Continuing Operations of 63734000.0 for Q1 2026, up 12.33% year-on-year from 56737000.0 in Q1 2025, and up 38.75% on a QoQ basis from 45933000.0 in Q4 2025.

Catalyst Pharmaceuticals (CPRX) has 17 years of Income from Continuing Operations data on file, last reported at 63734000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Income from Continuing Operations rose 12.33% year-over-year to 63734000.0; the trailing twelve-month figure through Mar 2026 stood at 214558000.0 (up 14.19% YoY), and the FY2025 full-year result was 207561000.0, up 34.4% from the prior year.
  • Income from Continuing Operations for Q1 2026 stood at 63734000.0, up from 45933000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 63734000.0 in Q1 2026 and bottomed at 30764000.0 in Q3 2023.
  • The 5-year median for Income from Continuing Operations is 37762000.0 (2023), against an average of 33599823.53.
  • The widest annual swing landed in 2022, when Income from Continuing Operations surged 267.96%; it then slumped 235.24% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 34253000.0 in 2022, then sank by 50.26% to 17039000.0 in 2023, then surged by 172.8% to 46483000.0 in 2024, then retreated by 1.18% to 45933000.0 in 2025, then jumped by 38.75% to 63734000.0 in 2026.
  • The last three Income from Continuing Operations figures came in at 63734000.0 (Q1 2026), 45933000.0 (Q4 2025), and 52783000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.99 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -8.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -14.46 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.03 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -3.40 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 727.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 205.99 Mn
10 Catalyst Pharmaceuticals 3.82 Bn 3.07 Bn 134.92 Mn 63.73 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 63.73 Mn
Dec 31, 2025 45.93 Mn
Sep 30, 2025 52.78 Mn
Jun 30, 2025 52.11 Mn
Mar 31, 2025 56.74 Mn
Dec 31, 2024 46.48 Mn
Sep 30, 2024 43.88 Mn
Jun 30, 2024 40.79 Mn
Mar 31, 2024 23.28 Mn
Dec 31, 2023 17.04 Mn
Sep 30, 2023 -30.76 Mn
Jun 30, 2023 37.76 Mn
Mar 31, 2023 29.57 Mn
Dec 31, 2022 34.25 Mn
Sep 30, 2022 22.75 Mn
Jun 30, 2022 21.62 Mn
Mar 31, 2022 13.24 Mn
Dec 31, 2021 9.31 Mn
Sep 30, 2021 10.33 Mn
Jun 30, 2021 12.18 Mn
Mar 31, 2021 7.66 Mn
Dec 31, 2020 11.44 Mn
Sep 30, 2020 43.34 Mn
Jun 30, 2020 9.78 Mn
Mar 31, 2020 10.43 Mn
Dec 31, 2019 7.93 Mn
Sep 30, 2019 13.63 Mn
Jun 30, 2019 10.96 Mn
Mar 31, 2019 -644,503.00
Dec 31, 2018 -14.50 Mn
Sep 30, 2018 -7.84 Mn
Jun 30, 2018 -5.97 Mn
Mar 31, 2018 -5.70 Mn
Dec 31, 2017 -5.39 Mn
Sep 30, 2017 -4.18 Mn
Jun 30, 2017 -3.88 Mn
Mar 31, 2017 -4.97 Mn
Dec 31, 2016 -4.16 Mn
Sep 30, 2016 -3.95 Mn
Jun 30, 2016 -4.57 Mn
Mar 31, 2016 -5.39 Mn
Dec 31, 2015 -5.82 Mn
Sep 30, 2015 -4.45 Mn
Jun 30, 2015 -4.56 Mn
Mar 31, 2015 -5.41 Mn
Dec 31, 2014 -3.49 Mn
Sep 30, 2014 -5.01 Mn
Jun 30, 2014 -3.20 Mn
Mar 31, 2014 -3.81 Mn
Dec 31, 2013 -1.35 Mn
Sep 30, 2013 -5.91 Mn
Jun 30, 2013 -3.14 Mn
Mar 31, 2013 -1.74 Mn
Dec 31, 2012 -76,585.00
Sep 30, 2012 -2.62 Mn
Jun 30, 2012 -289,080.00
Mar 31, 2012 -1.09 Mn
Dec 31, 2011 -2.35 Mn
Sep 30, 2011 -1.13 Mn
Jun 30, 2011 -1.39 Mn
Mar 31, 2011 -1.52 Mn
Dec 31, 2010 -728,754.00
Sep 30, 2010 -903,985.00